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Abstract
The coronavirus SARS-CoV-2 remains an extant threat against public health on a global scale. Cell infection
begins when the spike protein of SARS-CoV-2 binds with the cell receptor, angiotensin-converting enzyme 2
(ACE2). Here, we address the role of Tetracycline as an inhibitor for the receptor-binding domain (RBD)
of the spike protein. Targeted molecular investigation show that Tetracycline binds more favorably to the
RBD (-9.40 kcal/mol) compared to Chloroquine (-6.31 kcal/mol) or Doxycycline (-8.08 kcal/mol) and inhibits
attachment to ACE2 to a greater degree (binding efficiency of 2.98 kcalmol·nm2 for Tetracycline-RBD, 5.59
kcal
mol·nm2 for Chloroquine-RBD, 5.16
kcal
mol·nm2 for Doxycycline-RBD). Stronger Tetracycline inhibition is
verified with nonequilibrium PMF calculations, for which the Tetracycline-RBD complex exhibits the lowest
free energy profile along the dissociation pathway from ACE2. Tetracycline appears to target viral residues
that are usually involved in significant hydrogen bonding with ACE2; this inhibition of cellular infection
complements the anti-inflammatory and cytokine suppressing capability of Tetracycline, and may further
reduce the duration of ICU stays and mechanical ventilation induced by the coronavirus SARS-CoV-2.
I. Introduction
The extreme urgency for therapeutics against the
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) drives the review of existing drugs for their
ability to inhibit the function of this virus1;2.
Tetracycline has been proposed as a strong can-
didate against SARS-CoV-23 due to its lipophilic
nature, anti-inflammatory response, as well as its
ability to chelate zinc species on matrix metallopro-
teinases (MMPs). Tetracycline class antibiotics have
also been shown to be effective in reducing the dura-
tion of ventilatory support and ICU stay from acute
respiratory distress syndrome5, and Doxycycline
has been suggested to be an important component
in combination therapy for its anti-viral properties6.
Tetracycline as well as a broad band of related an-
tibiotics have been approved by the FDA4;7.
In this work, we quantify the performance of
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Tetracycline in inhibiting the binding of the SARS-
CoV 2 spike protein to ACE2. Tetracycline is found
to bind more favorably to the receptor binding do-
main (RBD) of the spike protein compared to Doxy-
cycline or Chloroquine, which was included in this
study as a baseline. The Tetracycline-RBD complex
also displays lower binding efficiency to the human
cell receptor ACE2.
II. Methods
The SARS-CoV 2 RBD, ACE2, Tetracycline,
and Chloroquine molecular structures were ob-
tained from RCSB PDB (6M0J, 2UXO, 4V2O,
2XRL)14;15;16;17. Missing hydrogen atoms were ap-
pended, after which structural preparation and
molecular docking with full ligand and protein
backbone flexibility were carried out using the
Rosetta suite18;19;20. The resulting complexes were
inspected manually, after which the binding affini-
ties of the best-scoring complexes were gauged us-
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ing MM/PBSA calculations after 100 ns equilibrium
molecular dynamics simulations21;22;23. The poten-
tials of mean force (PMF)24 along the dissociation
pathway of these RBD complexes from ACE2 were
found in LAMMPS25 using steered molecular dy-
namics after parameterization with CHARMM26.
Jarzynski’s equality was employed to calculate the
free energy profile for each RBD complex from 10
statistically independent trajectories27.
III. Results and Discussion
Tetracycline exhibits higher binding affinity to the
RBD in both blind and site-specific docking (-
9.40 kcal/mol) compared to Doxycycline (-8.08
kcal/mol) or Chloroquine (-6.63 vs 6.31 kcal/mol)
as delineated in Table 1. The amino acid residues
of the RBD involved in hydrogen bonding with
the Tetracycline molecule are Tyr 449, Asn 501, Gly
496, and Tyr 505 (Fig. 1), which have been shown
to be crucial for the SARS-CoV 2 RBD in binding
to ACE2 for cellular access8. These four residues
comprise major hot spots that form persistent hy-
drogen bonds with ACE2. Meanwhile, the amino
acids of RBD that interact with Chloroquine in the
site-specific configuration are Lys 356, Arg 454, Arg
466 and Arg 355, of which none are involved in
extended hydrogen bonding with ACE2.
Tetracyline appears to bind preferably to polar
or slightly lipophilic RBD residues, which com-
prise the majority of amino acids that form persis-
tent hydrogen bonds with ACE28;9. Other tetracy-
cline derivatives as Doxycycline or Minocycline are
known to be more lipophilic3;4;9 and may therefore
prefer nonpolar residues10 that are often buried be-
neath the solvent accessible surface area of the spike
protein. Indeed, the RBD residues that have highest
binding affinity to Doxycycline are Tyr 449, Gly 447,
Val 445, Gly 496, of which only two overlap with
RBD amino acids that engage in extended hydro-
gen bonding with ACE2. On the other end of the
spectrum, Chloroquine targets clusters of charged
residues on the RBD that do not actively participate
in hydrogen bonding with the cell receptor ACE2.
The binding efficiency13 (magnitude of binding
energy normalized by contact interface area) of
the SARS-CoV2 RBD-ACE2 complex was found
to be 7.58 kcal/(mol·nm2). In the presence of the
Figure 1: Interaction map of amino acid residues of the SARS-
CoV 2 receptor binding domain (RBD) that have the
highest binding affinity with Tetracycline. The Tyr
449, Asn 501, Gly 496 and Tyr 505 residues have
also been shown to form persistent hydrogen bonds
in maintaining the RBD-ACE2 complex 8.
Inhibitor ∆Gbind (kcal/mol) ∆Gbind (kcal/mol)
to RBD This work Prior literature
Tetracycline −9.40 N/A
Doxycycline −8.08 N/A
Chloroquine −6.31 [-5.3, -7.1]11;12
Table 1: The binding free energy of small-molecule inhibitors
to the SARS-CoV2 receptor binding domain (RBD).
Tetracycline binds preferably to the RBD.
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Figure 2: The hydrogen bonding lifetimes of binding site
residues of the inhibited RBD with ACE2 sustained
in 100 ns of simulation time, normalized by hydro-
gen bonding lifetimes in the uninhibited RBD-ACE2
complex.
protein-ligand complex Tetracycline-RBD, the bind-
ing efficiency with ACE2 (2.98 kcal/(mol·nm2)) is
significantly lower than that for Chloroquine-RBD
(5.59 kcal/(mol·nm2)) and Doxycycline-RBD (5.16
kcal/(mol·nm2)) as displayed in Table 2. A survey
of hydrogen bonding lifetimes between the impor-
tant binding site residues in the RBD with ACE28
shows that the Tetracycline inhibited RBD exhibits
the least hydrogen bonding activity with ACE2 (Fig.
2). This suggests that not only does Tetracycline
bind more favorably to the receptor binding domain
of the spike protein, it also inhibits the binding of
the RBD to ACE2 to a greater degree.
To verify this statement, steered molecular dy-
namics simulations were carried out to find the
potential of mean force (PMF) along a singular dis-
sociation pathway for the inhibited and uninhibited
RBD-ACE2 complexes. Figure 3 shows that the
PMF for unbinding of the Tetracycline-RBD com-
plex from ACE2 was lowest of the three structures
tested, which is in agreement with the binding effi-
ciencies found from equilibrium simulations. This
disruption of the RBD-ACE2 interface may there-
fore inhibit the signaling cascade initiated during
binding of the viral spike protein.
Complex Binding efficiency
to ACE2 (kcal/(mol·nm2))
RBD 7.58
Chloroquine-RBD 5.59
Doxycycline-RBD 5.16
Tetracycline-RBD 2.98
Table 2: The binding efficiency13 (magnitude of binding en-
ergy normalized by contact interface area) of the
spike protein RBD as well as the Tetracycline-RBD,
Doxycycline-RBD and Chloroquine-RBD complexes
to the human cell receptor ACE2. Binding efficiency
is lowest for the Tetracycline-RBD complex, indicat-
ing that Tetracycline is a more effective inhibitor.
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Figure 3: The potential of mean force (PMF) as a function
of the distance between the centers of masses of the
spike protein RBD complexes and the cell receptor
ACE2. The Tetracycline-RBD complex exhibits the
lowest free energy profile along the dissociation path-
way.
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IV. Conclusion
The tetracycline class of antibiotics, including Tetra-
cycline, Oxytetracycline, and Doxycycline may be
helpful in the fight against the coronavirus SARS-
CoV-2, due to its preferential association with the
important residues in the viral receptor binding
domain and the resulting strong inhibition of the
RBD-ACE2 complex. Further experimental studies
are recommended to validate how this reduction
of cellular infection complements or enhances the
anti-inflammatory and anti-viral properties of tetra-
cyclines in their role as treatment for SARS-CoV-2.
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